You are here

Biologx

Help Us Achieve Our Goal of Bringing
More Affordable Insulin to US Patients

We intend to sell our insulin for $25-$50 per vial in the USA. With these reduced prices, our goal is to operate a profitable company while helping save lives for those who would otherwise not be able to afford insulin.

The companies that sell Insulin in the USA are making huge profits at the expense of patients’ lives lost.

Through Our Proprietary Technology,
Our Goal is to Bring Affordable Insulin to the Patient

Your investment will help us quickly bring our Insulin to market.*

Diabetes has been growing at an exponential rate, and your investment could help bring affordable insulin to the nearly 463 Million people living with diabetes


The Rising Price of Insulin Is Deadly

“Stories of Americans rationing insulin - and dying for it - have been making national headlines. The most famous case, perhaps, was 26-year-old Alec Smith, who died in 2017 less than a month after he aged out of his mother's health insurance plan. Despite working full-time making more than minimum wage, he could not afford to buy new insurance or pay the $1,000 a month for insulin without it. Biologx Insulin Price Chart

Reports suggest that insulin prices are influenced by the major pharmaceutical companies, and in some cases appear to have cost diabetic patients their lives. Insulin is a hormone produced by the pancreas and is critical for the regulation of glucose (sugar) in the blood. We are passionate about bringing affordable insulin to the market. Invest now to help us save lives.


BiologX Product Pipeline

We have an active pipeline of products in various stages of development: Biologx Product Pipeline

images

Real Stories From Diabetic Patients

“Boyle died because he was $50 short of reaching his $750 GoFundMe goal to pay for a month's supply of insulin”

– VICE, MAY 2017: The High Price of Insulin is Literally Killing People

“Nobody cared or nobody understood that without this next vial of insulin, I wouldn't live to see another week”

– Kristen Whitney Daniels: CBS NEWS, 2019

“Woman says her son couldn't afford his insulin – now he's dead”

– CBS NEWS: Mother Fights for Lower Insulin Prices After Son's Tragic Death

BiologX Proprietary Insulin Production Can Save Lives

When we set out to make high quality insulin affordable, we worked hard to eliminate inefficiencies throughout the production process. BiologX has devised unique processes for the production of recombinant human insulin (RHI) that enable us to make more insulin in a shorter period of time – all at affordable costs to patients worldwide. Our life-saving insulins meet or exceed USP Reference Standards, the highest quality standards in the market.*

The Result

BiologX intends to price our Insulin at rates that will be more affordable to patients - because we believe it’s essential to enable easy affordable access to Insulin and because we can make a reasonable profit while doing so.*
*BiologX's insulin product candidate has not yet been approved by the FDA.

full height

Why Invest in BiologX?

Save Lives | Solve Global Problem | Invest for Good
Market Value Global Insulin Market is projected to reach $27.71 billion by 2025.1
Growth Rate Compound Annual Growth Rate (CAGR) of 3.4% during the forecast period.1
Demand Increase An estimated 463.0 million adults (age 20–79) worldwide have diabetes. By 2030 a projected 578.4 million, and by 2045, 700.2 million adults will be living with diabetes.2
1Human Insulin Market Size, Share & Industry Analysis, By Type (Analogue Insulin (Long-Acting, Fast Acting, Premix), Traditional Human Insulin (Long-Acting, Short-Acting, Fast Acting, Premix)), By Diabetes Type (Type 1, Type 2), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), and Regional Forecast, 2019-2026, Fortune Business Insights
 
2IDF Diabetes Atlas, 9th ed., (2019)

Investment Opportunity

logo

Did You Know You Can Invest With Your Self Directed IRA?

Click here to learn more about how you can invest in BiologX using your IRA. Or feel free to reach out to us by clicking on the blue "Contact" button at the top right hand corner of the page and we would be happy to discuss the process with you.

Important Note on Stock Liquidity

Please note that BiologX intends to list its stock on an ATS (Alternative Trading System) at the completion of our Reg A+ offering.

An ATS is an after-market exchange where people that own securities can buy and sell them. Because all Reg A+ offerings are Public Offerings, listing Reg A+ securities after the Reg A+ completes on an ATS is a useful way for BiologX to provide liquidity to its investors. One big advantage of ATS exchanges is that shorting of stocks is not possible and naked shorting is also not possible. Please don't hesitate to reach out to us with any questions.


Meet The Team

team member

Ron Zimmerman

Co-Founder & Chief Science Officer

×

Ron Zimmerman

Co-Founder & Chief Science Officer

Ron has extensive experience leading specialty pharmaceutical companies. Prior to founding ZBP, he was the Founder & President of Elona Biotechnologies, Inc., a technology leader in proteomics, process development and characterization of therapeutic proteins. With offices, laboratories and production facilities located south of Indianapolis, the company was involved in the development and production of human insulin, insulin analogs, growth hormones, and other “follow-on” proteins to treat chronic diseases. Ron was also a founding member of the management team that grew Indiana Protein Technologies into a successful specialty pharmaceutical company and managed its acquisition by IVAX Corp (now part of Teva Pharmaceutical Industries Limited) in 2006. Ron spent a significant part of his career as Chief Scientist with Eli Lilly & Company for 28 years. He holds a Master of Science in Physiology & Biology and a Bachelor of Science in Physiology from Indiana State University. He is published in several peer-reviewed scientific publications and holds multiple patents in innovative production processes for both novel and bioequivalent protein products.

team member

David Wood

President & Chief Executive Officer

×

David Wood

President & Chief Executive Officer

David Wood brings 30+ years of expertise as a strategic and growth-oriented operations executive with a track record of building business, delivering revenue growth, and creating world-class operational structures to sustain growth and profitability. He has experience as President, COO, VP/General Manager and Board of Directors member for public and private companies. David served as Chief Restructuring Officer for Scient, Inc., a consulting company founded in 1997 where he had also served as VP/GM for the Enterprise Business Unit, building it to a $180 million business. Prior to that he was President & COO of an international consumer products company creating $400 million in shareholder value, validated by Credit Suisse First Boston during an expansion-financing round. Earlier in his career, David held various executive and operations roles with PepsiCo. Before entering the private sector, David was a Captain in the United States Army, Field Artillery. He holds a Bachelor of Science, Economics, Cum Laude, from Northeastern University.

team member

Dr. Donna Zimmerman

Vice President of Regulatory Affairs Nominee

×

Dr. Donna Zimmerman

Vice President of Regulatory Affairs Nominee

Dr. Zimmerman has 30+ years of experience at a senior level in the life sciences industry, in clinical and regulatory affairs, IND, NDA and regulatory submission, and clinical study management. Prior to co-founding ZBP, she was the CFO and Head of Clinical and Regulatory Affairs of Elona Biotechnologies, Inc. Dr. Zimmerman was also the Director, Clinical and Regulatory Affairs of Indian Protein Technologies, managing the financial aspects of the company until its acquisition by IVAX Corp (now part of Teva Pharmaceutical Industries Limited) in 2006. She founded and led a clinical trial management company, responsible for managing all aspects of clinical trials for multiple clients simultaneously. Dr. Zimmerman is a private pilot, holds a PhD in Health Research Administration from Kennedy Western University, a Master of Business Administration from Indiana Wesleyan University, a Bachelor of Science in Chemistry & Biology from the University of Indiana, and an Associate of Science in nursing from Colorado State University.

team member

Dr. Alexander Fleming

Chief Medical Officer Nominee

×

Dr. Alexander Fleming

Chief Medical Officer Nominee

Dr. Fleming received his M.D. in Internal Medicine training from Emory followed by fellowships at Vanderbilt and NIH. At the FDA, he led clinical reviews of biotech products including metformin, insulin analogs, statins, and human insulin. Dr. Fleming is also an author of multiple medical and scientific papers, and is a major contributor to FDA’s Good Review Practice (GRP) initiative.

Board of Advisors

Roger Harrison, PhD

Executive, Consultant

Robert L. Zied

Entrepreneur

David Wamsley

Finance Expert

Anthony Moravec

Entrepreneur

Rod Turner

Finance Expert


BiologX, Inc. was formed in November 2020. BiologX, Inc. has never had any common officers, directors, or shareholders with Sixty-Six Oil Field Services, Inc. (“SSOF”) and BiologX, Inc. is not related to SSOF in any way. Click here to read more.


Global Diabetes Impact

460M Diabetics Worldwide*
1 in 10 Americans*
Of AllU.S. Deaths*

References

*Unless otherwise indicated, facts and figures regarding demand, sales, and cost of insulin are referenced from the Centers for Disease Control and Prevention (CDC) and the International Diabetes Federation.

Are You Ready to Save Lives?

Help us bring our affordable insulin to market with an investment today.

Updates

July 26
Insulin Rationing: A Common Practice with Deadly Consequences

One in four insulin-dependent diabetics ration their insulin because they cannot afford to use it in the doses prescribed. This is just one of many shocking statistics reported in an article published in JAMA Internal Medicine in 2019.

As insulin prices have only continued to rise since that study concluded, it is likely even more diabetics have turned to this drastic—and deadly—practice.

According to commentary provided by Elisabeth Rosenthal, MD, editor-in-chief of Kaiser Health News, that was included with the study results, rationing insulin can have serious health consequences.

“It can hasten disability (eg. blindness and kidney failure) and early death. Thanks to tight glucose control and more precise insulin dosing, researchers estimated in 2012 that children with diabetes born between 1965 and 1980 were living 15 years longer than those born between 1950 and 1965. Will that 15-year gain now be erased because of the price?”

According to the study and others like it, insulin rationing isn’t just a problem for those who are uninsured. Most patients who report insulin rationing have some kind of private or employer provided healthcare plan with high deductibles or high cost sharing. These people tend to be mostly middle-class and make a decent wage.

More affordable healthcare options that are readily available to all Americans would be a helpful step to reducing the practice of insulin rationing. But the more immediate solution to this problem is reducing the price of insulin through the introduction of competitive, effective biosimilars to the marketplace.

July 22
Insulin Biosimilars: What Are They and Why Do We Need More of Them?

You’ve heard of generic medication, but have you ever heard of a biosimilar?

This term has recently become more popular outside the pharmaceutical world thanks to a congressional ruling meant to increase competition in the biologics market.

If you’re confused about what this word means and the pros and cons of biosimilars, you're not alone. In this article, we’ll walk you through everything you need to know about biologics, biosimilars, and how the two interact to make prescriptions more affordable for all.

What Is a Biosimilar?

A biosimilar is a biological product with a very similar structure and function to a previously FDA-approved biologic drug.

Unlike traditional medications, biologics are made from living organisms or parts of living organisms. The molecules that make them up are much larger and more complex than non-biologic synthetic medications.

One of the most well-known biologics is insulin, which is made of highly complex peptides. Some other well-known examples include vaccines, botox, and growth factor products.

Novel biological medications are called biologics. Any reproduced versions created to be highly similar to these originals are called biosimilars.

Is a Biosimilar the Same as a Generic?

Because traditional medications are made synthetically, it is very easy to reproduce the formula to make an identical product. When this occurs, the subsequent formulations are known as generics.

But the process of reproducing biologics is far more complicated. Without access to the patented method of production, recreations of these types of drugs can be very similar to the original but never exactly the same.

When a recreation has a highly similar structure and function as the reference product, it is eligible to be named a biosimilar. The FDA tests these products to assure they have no clinically meaningful differences in safety, purity, or potency compared to the reference drug.

In terms of the market, biosimilars and generics play a very similar role. This is something we will touch on further down the page.

Why Are Biosimilars Just Now Becoming Available?

The first biosimilar was approved by the FDA in 2015, five full years after the Biologics Price Competition and Innovation Act was passed.

The lack of biosimilars hitting the market had a lot to do with legal injunctions being filed by companies who owned the patents to the biologics being reproduced. 

More recently, congressional rulings and changes put in place by the FDA have made it easier for companies to create and launch biosimilars.

In the last few years, we have seen many new biosimilars hit the market. The number of biosimilar insulins, however, remains very small. Those that are currently available are made by the same three companies that produce all of America’s name-brand insulins.

Are Biosimilars as Good as Name-Brand?

One requirement for biosimilars to obtain FDA approval is they must produce the same results as the reference product. They must be just as effective, just as potent, and just as safe.

There can be no clinically meaningful differences in how the biosimilar performs or in the side effects it has.

You can feel confident that any biosimilar on the market will work as well as the reference product it was made to emulate.

How Can Biosimilars Reduce Insulin Prices?

Like generic drugs, biosimilars are marketed at a much lower price than name-brand options. Not only does this give the customer a more affordable option for their treatment, but, over time, biosimilars help drive down the cost of the original reference drug as well.

If a drug is available that produces the same results as the original but costs less, the only choice the name-brand company has in order to compete is to lower the price of their product.

In the insulin market, this kind of competition is something that has long been lacking.

Currently, only three companies produce insulins that are approved for use in the United States. The market price of these name-brand insulins far exceeds the production costs of each drug. But, without more affordable options, the companies have no reason to lower their prices (or their profit margins).

Some of these companies have produced their own biosimilars in the hopes of appeasing congress’ appeal for lower insulin prices. Unfortunately, these big-name companies control where their cheaper drugs are distributed and can easily manipulate the market so their high-priced, name-brand products remain the most accessible option.

The key to truly lowering insulin prices is to foster real competition by introducing effective and affordable biosimilars created by new companies dedicated to seeing their products become a success.

July 20
Broadening Cheap Insulin Choices Is Key to Saving Lives

Two years ago, the effectiveness of OTC insulins, the cheapest type of insulin currently available, was called into question. This came after the death of Josh Wilkerson, aged 27, made headlines. 

Wilkerson died just months after switching from an analog insulin to the much cheaper OTC type. He was forced to make the switch after he aged off his parent’s insurance plan.

OTC insulins are less commonly prescribed than the newer, more predictable analog types. But these older insulins tend to be much cheaper—often up to ten times cheaper—and are often sought out by those who are uninsured or underinsured.

Despite many claims to the contrary, OTC insulins have a similar efficacy as more expensive analog types. Studies have found that while OTC insulins cause more frequent hypoglycemia, people taking them tend to have similar A1C levels as those using analogs.

But OTC insulins do behave very differently from analogs. They have less predictable and longer absorption rates. And they peak instead of absorbing gradually over a set period.

The problem in situations like Wilkerson’s is not that he was forced to buy an ineffective insulin. It is that he was forced to buy a type of insulin that he had no experience with and that his body did not tolerate well. 

People living with diabetes should have access to affordable insulins that they are familiar with and that they know will work well for them. This means creating a line of low-priced, effective insulins that include analogs as well as OTCs; fast-acting and rapid-acting as well as long-acting. That is exactly what BiologX is trying to do.

July 15
What is Insulin and What Are the Different Types Available?

What is Insulin?

Insulin is a hormone made by the pancreas. It allows your body to use glucose, a type of sugar found in many carbohydrates, for energy. After eating, the digestive tract breaks down carbohydrates and changes them into glucose that is then absorbed into your bloodstream through the lining in your small intestine. Once glucose is in your bloodstream, insulin causes cells throughout your body to absorb the sugar and use it for energy. 

Insulin also helps balance your blood glucose levels. When there’s an excess of glucose in your bloodstream, insulin signals your body to store that in your liver. The stored glucose isn’t released until your blood glucose levels decrease e.g., between meals or when your body is stressed or needs an extra boost of energy

Diabetes occurs when your body either does not produce insulin (Type 1) or it does not produce enough insulin (Type 2). Injections of insulin can help treat both types of diabetes, replacing or supplementing the body’s insulin.  People with type 1 diabetes can’t make insulin, so they must inject insulin to control their blood glucose levels. Those with type 2 diabetes potentially can manage their glucose levels by lifestyle changes or oral medication. But eventually, even type 2 diabetics may simply not be making enough insulin, and also need insulin to control their blood glucose levels.

What are the Different Types of Insulin Available?

There are multiple types insulin available to treat diabetes and all insulins produce the same effect: they mimic the natural ebbs and flows of insulin levels in the body during the day. The different types vary in how quickly they work, their peak and how long they last. Some work quickly while others work a little slower. Some last for a longer time in your body, while some have a short life.

Here’s a quick glance at commonly used insulin and how they work:

INSULIN TYPE HOW SOON IT BEGINS TO WORK? HOW LONG IT LASTS?
Rapid Acting Insulin 15 min 3 to 5 hrs
Short Acting Insulin 30-60 min 5 to 8 hrs
Intermediate Acting Insulin 1-3 hrs 10 to 16 hrs
Long Acting Insulin 1 hr Up to 24 hrs or more
Pre-Mixed Insulin 5-15 min 10 to 16 hrs

Rapid-acting insulin

Rapid-acting insulin (bolus insulin) is typically used to provide a surge of insulin at mealtime to lower glucose levels after eating. It acts very fast beginning to work approximately 15 minutes after injection, and lasts between 3 - 4hours. It can either be injected or used in an insulin pump.

Short-acting insulin

Short-acting insulins (regular insulin) are not as quick to act as rapid acting insulins it usually takes effect between 30 and 60 minutes. It’s usually taken before a meal to control postprandial blood glucose levels and is longer-lasting than rapid-acting insulin, being effective between 5 – 8 hours.

Intermediate-acting

Intermediate-acting insulin starts working in one to two hours and lasts about 10 to 16 hours. It is typically used to maintain a low and steady level of insulin in the body throughout the day. It is known as basal or background insulin replacement  and is intended to be administered twice per day.

Long-acting insulin

Long-lasting insulin is similar to immediate-acting insulin in that it offers a steady level of insulin. But it’s meant to last 20 to 24 hours so that you only have to take it once per day.

Pre-mixed insulin

In premixed insulin, shorter or rapid acting insulin is combined with longer acting insulin.

July 12
Insulin Prices Continue to Rise as Costs to PBMs Fall

“The U.S. represents only 15% of the global insulin market, but generates nearly 50% of the industry’s insulin revenue.”

This shocking stat comes from an article on insulin price inflation that was published by Forbes earlier this year.

The article calls to attention the discrepancies between the rising prices of insulin to the user and the falling net costs of insulin to pharmacy benefit managers (PBMs). This cost reduction is fueled in large part by steep rebates that are not being passed on to the customer.

The rising price of insulin has huge implications on those who rely on these products to stay alive, as the article is quick to point out.

“Roughly a quarter of diabetic patients dependent on insulin skimp or even skip doses altogether.”

The article concludes by outlining a “multi-pronged” approach to reigning in the ever-rising prices of insulin. What this plan fails to take into account is the need for more competition within the insulin market.

Increasing access to health insurance and passing rebates onto customers will help make insulin more affordable to many. But the only thing that can truly drive down the list price of these products is a similar product, that is just as effective, being marketed at a lower price.

  •  

Comments

Post comment

BiologX on July 03
It will have no impact on our strategy. When we introduce our insulin we’ll be happy to partner with Wal-Mart (and all pharmacies) so they can further lower the price of insulin. Because of our proprietary IP, we expect our manufacturing system to produce top tier insulin at significantly lower costs than existing producers, so we’ll be able to supply pharmacies at BiologX prices, not current prices.

Gary Hunt on July 03
Will I get update on stock value

BiologX on July 03
Yes you will. Updates will be posted on this site and all our sites as well. Also, please email us with any questions you might have at any time.

Gary Hunt on July 02
Will Walmart have any effect on what you are trying to accomplish

Gary Hunt on July 01
Will I get updates on Biologx in my emails

BiologX on July 01
Yes you will. Updates will be posted on this site and all our sites as well. Also, please email us with any questions you might have at any time.

  •  

Offering Circular

Please read the Offering Circular here: Get Offering Circular

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. YOU MAY OBTAIN A COPY OF THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT FROM:

https://www.manhattanstreetcapital.com/offering-circular/25008

YOU SHOULD READ THE OFFERING CIRCULAR BEFORE MAKING ANY INVESTMENT.